Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COLL Collegium Pharmaceutical	$30.30 +2.5%	$28.98	$23.23 ▼ $42.29	$950.14M	0.64	398,219 shs	267,653 shs
ELVN Enliven Therapeutics	$19.65 -2.0%	$19.43	$13.30 ▼ $30.03	$984.33M	0.83	293,183 shs	884,482 shs
LFCR Lifecore Biomedical	$7.96 -2.0%	$6.95	$3.68 ▼ $8.63	$300.65M	0.71	228,579 shs	113,725 shs
PAHC Phibro Animal Health	$26.62 +4.2%	$22.99	$16.16 ▼ $26.77	$1.04B	0.75	211,856 shs	271,863 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COLL Collegium Pharmaceutical	+2.47%	+0.63%	+3.10%	+1.00%	-7.11%
ELVN Enliven Therapeutics	-2.04%	-7.14%	+10.15%	-1.06%	-13.44%
LFCR Lifecore Biomedical	-1.97%	-3.86%	+20.42%	+10.56%	+68.64%
PAHC Phibro Animal Health	+4.23%	+7.47%	+8.30%	+21.55%	+56.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COLL Collegium Pharmaceutical	4.0149 of 5 stars	3.4	1.0	0.0	3.0	1.6	0.8	2.5
ELVN Enliven Therapeutics	2.2738 of 5 stars	3.5	0.0	0.0	0.0	2.6	4.2	0.0
LFCR Lifecore Biomedical	1.5857 of 5 stars	1.3	2.0	0.0	0.0	3.8	4.2	0.6
PAHC Phibro Animal Health	3.6413 of 5 stars	0.8	2.0	2.5	1.1	3.0	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COLL Collegium Pharmaceutical	2.75	Moderate Buy	$43.75	44.39% Upside
ELVN Enliven Therapeutics	3.00	Buy	$39.60	101.53% Upside
LFCR Lifecore Biomedical	2.50	Moderate Buy	$8.00	0.50% Upside
PAHC Phibro Animal Health	1.67	Reduce	$21.80	-18.11% Downside

Current Analyst Ratings Breakdown

Latest LFCR, ELVN, PAHC, and COLL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/16/2025	ELVN Enliven Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $52.00
6/16/2025	ELVN Enliven Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
5/21/2025	LFCR Lifecore Biomedical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
5/16/2025	ELVN Enliven Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $27.00
5/15/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/9/2025	COLL Collegium Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$36.00 ➝ $37.00
5/8/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $21.00
4/15/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$20.00

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COLL Collegium Pharmaceutical	$631.45M	1.54	$12.63 per share	2.40	$7.10 per share	4.27
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$6.34 per share	N/A
LFCR Lifecore Biomedical	$128.26M	2.30	N/A	N/A	$0.37 per share	21.51
PAHC Phibro Animal Health	$1.02B	1.06	$2.20 per share	12.08	$6.34 per share	4.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COLL Collegium Pharmaceutical	$69.19M	$1.22	24.84	5.03	N/A	6.61%	99.08%	15.14%	8/6/2025 (Estimated)
ELVN Enliven Therapeutics	-$89.02M	-$1.92	N/A	N/A	N/A	N/A	-31.84%	-30.09%	8/12/2025 (Estimated)
LFCR Lifecore Biomedical	$12.01M	-$1.45	N/A	N/A	N/A	-35.90%	-551.09%	-13.89%	8/15/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	34.13	12.68	0.48	2.68%	30.51%	6.89%	8/27/2025 (Estimated)

Latest LFCR, ELVN, PAHC, and COLL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/8/2025	Q1 2025	COLL Collegium Pharmaceutical	$1.50	$1.49	-$0.01	$0.07	$174.96 million	$177.76 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
4/3/2025	Q3 2025	LFCR Lifecore Biomedical	-$0.14	-$0.19	-$0.05	-$0.47	$33.23 million	$35.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.80%	N/A	61.54%	N/A

Latest LFCR, ELVN, PAHC, and COLL Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COLL Collegium Pharmaceutical	3.30	1.08	1.01
ELVN Enliven Therapeutics	N/A	21.07	21.06
LFCR Lifecore Biomedical	66.36	2.71	1.59
PAHC Phibro Animal Health	2.67	2.91	1.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COLL Collegium Pharmaceutical	N/A
ELVN Enliven Therapeutics	95.08%
LFCR Lifecore Biomedical	83.36%
PAHC Phibro Animal Health	99.34%

Insider Ownership

Company	Insider Ownership
COLL Collegium Pharmaceutical	2.51%
ELVN Enliven Therapeutics	25.90%
LFCR Lifecore Biomedical	32.20%
PAHC Phibro Animal Health	50.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COLL Collegium Pharmaceutical	210	32.13 million	31.33 million	Optionable
ELVN Enliven Therapeutics	50	49.07 million	36.36 million	Optionable
LFCR Lifecore Biomedical	690	37.03 million	25.10 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable

LFCR, ELVN, PAHC, and COLL Headlines

Recent News About These Companies

Phibro Animal Health Stock Up 52.8% in a Year: What's Driving the Rise?

July 1 at 9:15 AM | zacks.com

Phibro Animal Health (NASDAQ:PAHC) versus Metastat (OTCMKTS:MTST) Critical Comparison

July 1 at 4:33 AM | americanbankingnews.com

PAHC vs. BSX: Which Stock Is the Better Value Option?

June 30 at 12:41 PM | zacks.com

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

June 30 at 10:40 AM | zacks.com

Phibro Animal Health (NASDAQ:PAHC) PT Set at $26.00 by Morgan Stanley

June 27, 2025 | americanbankingnews.com

Morgan Stanley Raises Phibro Animal Health (NASDAQ:PAHC) Price Target to $26.00

June 25, 2025 | marketbeat.com

Investors in Phibro Animal Health (NASDAQ:PAHC) have seen decent returns of 45% over the past year

June 25, 2025 | finance.yahoo.com

Best Growth Stocks to Buy for June 25th

June 25, 2025 | zacks.com

Phibro Animal Health Corporation (PAHC) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Is Phibro (PAHC) a Solid Growth Stock? 3 Reasons to Think "Yes"

June 23, 2025 | zacks.com

Zacks Research Issues Optimistic Forecast for PAHC Earnings

June 19, 2025 | marketbeat.com

Reasons to Add PAHC Stock to Your Portfolio Right Now

June 18, 2025 | zacks.com

BNP Paribas Upgrades Phibro Animal Health (NASDAQ:PAHC) to "Hold"

June 18, 2025 | marketbeat.com

Sowell Financial Services LLC Takes $1.98 Million Position in Phibro Animal Health Corporation (NASDAQ:PAHC)

June 18, 2025 | marketbeat.com

GAMMA Investing LLC Has $784,000 Stock Position in Phibro Animal Health Corporation (NASDAQ:PAHC)

June 18, 2025 | marketbeat.com

Phibro Animal Health Co. (NASDAQ:PAHC) Given Consensus Recommendation of "Reduce" by Brokerages

June 16, 2025 | marketbeat.com

Phibro Animal Health (NASDAQ:PAHC) Upgraded at BNP Paribas Exane

June 16, 2025 | marketbeat.com

Harbor Capital Advisors Inc. Has $231,000 Holdings in Phibro Animal Health Co. (NASDAQ:PAHC)

June 15, 2025 | marketbeat.com

PAHC vs. BSX: Which Stock Should Value Investors Buy Now?

June 13, 2025 | zacks.com

4 Stocks Trading Near 52-Week High With More Upside Potential

June 13, 2025 | zacks.com

Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?

June 13, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR, ELVN, PAHC, and COLL Company Descriptions

Collegium Pharmaceutical NASDAQ:COLL

$30.30 +0.73 (+2.47%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$30.30 0.00 (-0.02%)

As of 07/1/2025 04:04 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Enliven Therapeutics NASDAQ:ELVN

$19.65 -0.41 (-2.04%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$19.65 0.00 (0.00%)

As of 07/1/2025 04:36 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Lifecore Biomedical NASDAQ:LFCR

$7.96 -0.16 (-1.97%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$7.96 +0.00 (+0.06%)

As of 07/1/2025 06:16 PM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Phibro Animal Health NASDAQ:PAHC

$26.62 +1.08 (+4.23%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$26.60 -0.02 (-0.06%)

As of 07/1/2025 04:04 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time